This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zorblisa

Amicus Therapeutics, Inc.

Drug Names(s): SD-101, Allantoin, SD-101 (Scioderm), SD101, SD 101

Description: SD-101 is a topical cream formulation of allantoin, which appears to have multiple wound-healing effects, including anti-inflammatory and antimicrobial activity and tissue formation and differentiation, specifically in stimulating development of granulations and a tendency towards epithelialization.

Deal Structure: Amicus and Scioderm
In August 2015, Amicus and Scioderm have signed a definitive agreement under which Amicus will acquire 100% of the capital stock of Scioderm.

Amicus will acquire Scioderm in a cash and stock transaction. At closing, Amicus will pay Scioderm shareholders $229 million, of which $125 million will be paid in cash and $104 million will be paid through the issuance of 7 million newly issued Amicus shares. Amicus has agreed to pay up to an additional $361 million to Scioderm shareholders in cash or stock upon achievement of certain clinical and regulatory milestones and $257 million to Scioderm shareholders in cash or stock upon achievement of certain sales milestones. If Zorblisa is approved, EB qualifies as a rare pediatric disease and a Priority Review Voucher will be requested. If the Priority Review voucher is obtained and subsequently sold, Amicus will pay Scioderm shareholders the lesser of $100 million or 50% of the proceeds of such sale....See full deal structure in Biomedtracker


Zorblisa News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug